Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer

Cancer Immunology Immunotherapy(2020)10.1007/s00262-020-02674-wSource: DataRank Database

Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer is a research paper published in Cancer Immunology Immunotherapy (2020). On theSindex it has a DataRank of 0.571. It has been cited 44 times.

N/A

0.571DataRank · unranked

Scored on demand from live citation data

Open Access44 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)OA: greenTopics (33)Linked Datasets (25)DataCite Reuse (25)IDs (PubMed, PMC)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.571

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (16)

Daniel Spakowicz ORCID,Songzhu Zhao,Sandip H. Patel ORCID,Andrew Johns ORCID,Madison Grogan ORCID

Live enrichment

PubMed:32728772 PMC:PMC7572636

National Institutes of Health

Grant: P30CA016058

National Cancer Institute

Grant: K12 CA133250

NCATS NIH HHS

Grant: UL1 TR002733

National Institutes of Health

Grant: 3P30CA016058-15S1

CORE--HORMONE RECEPTOR LABORATORY

National Institutes of Health

Grant: 5UL1TR002733-02

The OSU Center for Clinical and Translational Science: Advancing Today's Discoveries to Improve Health

National Institutes of Health

Grant: 2K12CA133250-16

OSU K12 Training Grant in Oncology

greenLicense: Springer TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7572636

publisherhttps://link.springer.com/content/pdf/10.1007/s00262-020-02674-w.pdf

publisherhttps://link.springer.com/article/10.1007/s00262-020-02674-w/fulltext.html

https://doi.org/10.1007/s00262-020-02674-w

https://europepmc.org/articles/pmc7572636?pdf=render

Fields of Study

03 medical and health sciences0302 clinical medicine

MeSH Terms

HumansNeoplasmsPneumoniaAdrenal Cortex HormonesAnti-Inflammatory AgentsAdministration, InhalationRetrospective StudiesAdultAgedMiddle AgedFemaleMaleAntineoplastic Agents, Immunological

Keywords

ImmunotherapyPneumonitisInhaled Corticosteroids (Ics)Immune-related Adverse Events (Irae)Immune Checkpoint Inhibitor (Ici)AdultMaleAnti-Inflammatory AgentsPneumoniaMiddle AgedAntineoplastic Agents, ImmunologicalAdrenal Cortex HormonesNeoplasmsAdministration, InhalationHumansFemaleAgedRetrospective Studies

Sustainable Development Goals

SDG 3: 3. Good health

Additional file 10 of The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials

10.6084/m9.figshare.16807562.v1figshare

10.6084/m9.figshare.16807562figshare

Additional file 11 of The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials

10.6084/m9.figshare.16807565.v1figshare

10.6084/m9.figshare.16807565figshare

Additional file 12 of The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials

10.6084/m9.figshare.16807568.v1figshare

10.6084/m9.figshare.16807568figshare

Additional file 13 of The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials

10.6084/m9.figshare.16807571.v1figshare

10.6084/m9.figshare.16807571figshare

Additional file 3 of The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials

10.6084/m9.figshare.16807580.v1figshare

10.6084/m9.figshare.16807580figshare

Additional file 4 of The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials

10.6084/m9.figshare.16807583.v1figshare

10.6084/m9.figshare.16807583figshare

Additional file 5 of The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials

10.6084/m9.figshare.16807586.v1figshare

10.6084/m9.figshare.16807586figshare

Additional file 6 of The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials

10.6084/m9.figshare.16807589.v1figshare

10.6084/m9.figshare.16807589figshare

Additional file 7 of The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials

10.6084/m9.figshare.16807595.v1figshare

10.6084/m9.figshare.16807595figshare

Additional file 8 of The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials

10.6084/m9.figshare.16807598.v1figshare

10.6084/m9.figshare.16807598figshare